When an early-stage entrepreneur is dealing with representatives of a much larger company, several issues come to the fore. Pfizer’s Mike Warner and Jim Mcloughlin, assistant general counsel and executive
When an early-stage entrepreneur is dealing with representatives of a much larger company, several issues come to the fore. Pfizer’s Mike Warner and Jim Mcloughlin, assistant general counsel and executive director, respectively, will explain the importance of Material Transfer Agreements; what’s in and what isn’t in a Confidential Disclosure Agreement, and how to manage multiple confidentiality obligations; why you may or may not want to match a new technology with a new or different business model; and more.
About the speakers
Jim McLoughlin, Ph.D., MBA is Executive Director for Worldwide Research and Development Business Development at Pfizer. Jim is based at Pfizer’s Rinat Laboratories in South San Francisco, California and is responsible to supporting technologies for Rinat’s immunooncology R&D and for Pfizer’s Global Precision Medline efforts, including preclinical and clinical imaging and applied genetics. In prior roles, Jim has supported compound out-licensing, safety sciences and pharmaceutical sciences and new technologies including genomic applications, proteomics and stem cell therapeutics.
This is Jim’s 15th year at Pfizer and prior roles included business development at Monsanto, project leader in Monsanto Agriculture and scientist at Chevron’s Research Technology Center. Jim has a Ph.D. in chemistry from the University of California at Riverside and an MBA from the Olin School at Washington University, St. Louis.
Mike Warner is Assistant General Counsel at Pfizer Inc. and General Counsel for Pfizer’s Rinat Pharmaceuticals subsidiary. He has more than 33 years of experience at Pfizer legacy companies. Before moving to California, Mike was head of Pfizer’s St. Louis Patent Department. His current responsibilities include transactions, outlicensing and divestitures as well as serving as counsel to Pfizer’s Pharmaceutical Sciences and Medicinal Chemistry divisions. Major projects include the spin-off of a Japanese pharmaceutical newco (RaQualia Pharmaceuticals); the sale of Esperion Therapeutics; and outlicensing of several products to biotech startups. Mike is also General Manager of Pfizer’s Coley Pharmaceuticals GmbH subsidiary. He took his B.S. in Chemistry at Centenary College of Louisiana, his Ph.D. in Organic Chemistry from Indiana University, and his J.D. from St. Louis University. Mike lives in San Mateo, California.
(Thursday) 12:00 am - 12:00 am